Current anti-inflammatory therapy for rheumatoid arthritis: efficacy issues (based on EULAR 2025 materials)
Open Access
- 17 August 2026
- journal article
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 106-112
Abstract
In modern rheumatology, the problem of rheumatoid arthritis (RA) treatment remains highly relevant. This is demonstrated by the numerous clinical trials of new drugs with an expanding range of mechanisms of action and studies of optimal treatment strategies using currently available medications conducted worldwide. This review analyzes materials prepared by EULAR experts on the efficacy of current disease-modifying antirheumatic drugs and glucocorticoids in the treatment of RA.Keywords
This publication has 31 references indexed in Scilit:
- Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trialThe Lancet Rheumatology, 2024
- Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open‐Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in RemissionArthritis & Rheumatology, 2024
- Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trialsThe Lancet Rheumatology, 2023
- Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 studyThe Lancet Regional Health - Western Pacific, 2023
- Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design studyThe Lancet Rheumatology, 2023
- Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid ArthritisRheumatology and Therapy, 2023
- Phase II/III Results of a Trial of Anti–Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2022
- The Efficacy of Short‐Term Bridging Strategies With High‐ and Low‐Dose Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A Double‐Blind, Randomized, Placebo‐Controlled TrialArthritis & Rheumatology, 2022
- Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trialThe Lancet Rheumatology, 2022
- Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialThe Lancet, 2021